ClinConnect ClinConnect Logo
Search / Trial NCT06872099

NAsal MEthicillin-resistant Staphylococcus (NAMES): a Prospective Study to Assess the Impact of Antibiotic Therapy on Nasal Colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) Inhospitalized Children

Launched by FONDAZIONE IRCCS POLICLINICO SAN MATTEO DI PAVIA · Mar 6, 2025

Trial Information

Current as of April 23, 2025

Recruiting

Keywords

ClinConnect Summary

The NAMES trial is studying how antibiotic treatment affects nasal colonization with a type of bacteria called Methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children. MRSA can cause infections that are difficult to treat because it resists many common antibiotics. The goal of this research is to find out how often children in the hospital carry MRSA in their noses and whether their antibiotic use during their stay influences this. By understanding these factors, the study aims to help improve how antibiotics are prescribed to children, reducing unnecessary use and the risk of antibiotic resistance.

To participate in this trial, children aged between 1 and 16 years who are hospitalized can be included, provided their parents or guardians agree to the study. Unfortunately, children with certain health conditions, such as those in cancer treatment or very young infants under one year old, cannot take part. If a child joins the study, they will be monitored for MRSA nasal colonization, and researchers will gather information about their antibiotic treatments. This trial is important because it seeks to optimize antibiotic use in children, which can help protect them from infections and improve their overall health outcomes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria: · All the hospitalized children, aged between 1 and 16 years.
  • Informed consent signed by parents or legal tutors
  • Exclusion Criteria: · All the hospitalized children admitted to the Unit of Oncologic/Hematologic disease or children affected with an hematologic disease also if admitted to the General Paediatric Ward.
  • All the hospitalized children admitted to the Paediatric Intensive Care Unit (PICU)
  • All the hospitalized children aged \< 1 years old
  • Children with parents or legal tutor who eventually refuse to sign the study consent form

About Fondazione Irccs Policlinico San Matteo Di Pavia

Fondazione IRCCS Policlinico San Matteo di Pavia is a prestigious research hospital and clinical trial sponsor located in Italy, dedicated to advancing medical knowledge and improving patient care through innovative research. As a leading institution in the fields of clinical and translational medicine, the foundation actively conducts trials across various therapeutic areas, emphasizing rigorous scientific methodologies and adherence to ethical standards. With a commitment to fostering collaboration among healthcare professionals, researchers, and patients, Fondazione IRCCS Policlinico San Matteo serves as a pivotal contributor to the development of new treatments and healthcare solutions, ultimately enhancing patient outcomes and public health.

Locations

Pavia, , Italy

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported